Any current/future new fundraising through debt or equity?

There is no mention of any current or planned new fundraising through debt or equity in the call. As of the latest update, borrowings stand at Rs. 1,196 crore with a healthy debt-to-equity ratio of 0.23. Short-term borrowings have increased due to higher working capital requirements but the company aims to reduce borrowings through cash flow and working capital release in FY'26. No indication of plans for equity issuance. CAPEX is expected to be around Rs. 400-450 crores for maintenance and completing existing projects, with no significant large new CAPEX projects planned. R&D spend is forecas

Any current/future capex/capital investment/strategic investment?

Major CAPEX projects for FY'25 included commissioning the Pithampur manufacturing facility, building a new peptide block for peptide manufacturing at API 2, and adding an additional injectable line at F3. These major projects are now over. Maintenance and regular CAPEX going forward is budgeted around Rs. 400-450 crores for FY'26, including some spillover expenses from existing projects. No significant new large CAPEX projects are expected in FY'26. Peptide block manufacturing is part of the CAPEX for strategic investment in complex injectables. Focus remains on augmenting manufacturing capaci

Future growth expectations in sales/revenue/volumes?

U.S. business expected to grow at mid to high teens (around 15%) in FY'26, driven by new product launches and volume growth. Rest of the World (ROW) business projected to grow between 12% to 15% in FY'26. API business anticipated to grow around 10% in FY'26. Indian business is positive about achieving double-digit growth (10%+) for FY'26, despite past challenges in anti-infective segment. Stable number of Medical Representatives (~5,500) with minor additions (~100) expected, indicating continuation of current sales efforts. Animal Health business continues strong growth (19% quarterl

Future growth expectations in earnings/operating earnings/profits/EPS?

U.S. business expected to grow mid to high teens (~15%) in FY'26, driven by new product launches and volume growth. Rest of World (ROW) business projected to grow between 12%-15%. API business anticipated growth of about 10%. India business optimistic for double-digit growth (~10%+) after recent market moderation. EBITDA margins targeted to improve over the next couple of years due to better facility utilization and cost optimization efforts. Operating leverage expected from new manufacturing facilities (especially injectables) coming on stream. R&D investment to increase to Rs. 60

Alembic Pharmaceuticals LtdQ4 FY25Pharmaceuticals & Biotechnology

Alembic Pharmaceuticals Ltd Q4 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹794.85P/E: 21.0Market Cap: ₹15.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

U.S. business expected to grow at mid to high teens (around 15%) in FY'26, driven by new product launches and volume growth.
Rest of the World (ROW) business projected to grow between 12% to 15% in FY'26.
API business anticipated to grow around 10% in FY'26.
Indian business is positive about achieving double-digit growth (10%+) for FY'26, despite past challenges in anti-infective segment.
Stable number of Medical Representatives (~5,500) with minor additions (~100) expected, indicating continuation of current sales efforts.
Animal Health business continues strong growth (19% quarterly, 21% annually) with robust product portfolio and new launches.
Ongoing efforts to optimize costs, improve utilization, and maintain R&D focus to support growth.
U.S. launches pipeline remains robust with 15+ planned in FY'26, with about 20%-30% considered high-value, less competition products.

Margin guidance

Category 3

U.S. business expected to grow mid to high teens (~15%) in FY'26, driven by new product launches and volume growth.
Rest of World (ROW) business projected to grow between 12%-15%.
API business anticipated growth of about 10%.
India business optimistic for double-digit growth (~10%+) after recent market moderation.
EBITDA margins targeted to improve over the next couple of years due to better facility utilization and cost optimization efforts.
Operating leverage expected from new manufacturing facilities (especially injectables) coming on stream.
R&D investment to increase to Rs. 600-650 crores in FY'26, supporting future product pipeline and growth.
EPS growth correlating with revenue and margin improvements, though no specific number was provided.
Overall, management confident of sustainable profit growth driven by multiple growth levers including launches, operational efficiencies, and market recovery.

See what Alembic Pharmaceuticals Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no mention of any current or planned new fundraising through debt or equity in the call.
As of the latest update, borrowings stand at Rs. 1,196 crore with a healthy debt-to-equity ratio of 0.23.
Short-term borrowings have increased due to higher working capital requirements but the company aims to reduce borrowings through cash flow and working capital release in FY'26.
No indication of plans for equity issuance.
CAPEX is expected to be around Rs. 400-450 crores for maintenance and completing existing projects, with no significant large new CAPEX projects planned.
R&D spend is forecasted to be Rs. 600-650 crores, funded from internal resources.
Overall, the company appears focused on optimizing existing resources and cash flow rather than raising fresh funds via debt or equity.

Order book

The transcript from Alembic Pharmaceuticals Limited's Q4 FY'25 earnings call does not specifically provide details regarding the current or expected order book or pending orders. No explicit numerical data or commentary on order backlog was mentioned during the call. The focus was on financial performance, revenue growth, R&D outlook, inventory levels, CAPEX, and market strategies, but order book status was not addressed. For precise information on order books or pending orders, one may need to refer to company filings or direct communications from management beyond this call.

See what Alembic Pharmaceuticals Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Major CAPEX projects for FY'25 included commissioning the Pithampur manufacturing facility, building a new peptide block for peptide manufacturing at API 2, and adding an additional injectable line at F3.
These major projects are now over.
Maintenance and regular CAPEX going forward is budgeted around Rs. 400-450 crores for FY'26, including some spillover expenses from existing projects.
No significant new large CAPEX projects are expected in FY'26.
Peptide block manufacturing is part of the CAPEX for strategic investment in complex injectables.
Focus remains on augmenting manufacturing capacity, improved logistics, and targeted R&D investment (guidance Rs. 600-650 crores for FY'26).
Past investments aim at increasing facility utilization and enabling operating leverage over the next few years.

Track Alembic Pharmaceuticals Ltd — get its next earnings analysis in your feed

How does Alembic Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisAlembic Pharmaceuticals Ltd

Rev 3Mar 3

See where Alembic Pharmaceuticals Ltd sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Alembic Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Compare Alembic Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company (Q4 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Alembic Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Alembic Pharmaceuticals Ltd Q4 FY25 Earnings Call Analysis

Revenue guidance

Fundraise plans

Capex plans

How does Alembic Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Continue your research

What Alembic Pharmaceuticals Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season